SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
33.86
+0.59 (+1.77%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close33.27
Open33.55
Bid33.89 x 1000
Ask34.00 x 900
Day's Range33.38 - 33.93
52 Week Range18.21 - 41.95
Volume84,600
Avg. Volume121,825
Market Cap596.752M
Beta (5Y Monthly)-0.37
PE Ratio (TTM)70.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (0.84%)
Ex-Dividend DateOct 22, 2019
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Simulations Plus to Present at the 22nd Annual Needham Growth Conference

    Simulations Plus announced that CEO Shawn O'Connor will attend and present at the Needham 22nd Growth Conference in New York City on January 15, 2020.

  • Business Wire

    Simulations Plus Reports Record First Quarter FY2020 Financial Results

    Simulations Plus today reported record 1st quarter results for fiscal year 2020. Net revenues of $9.4 million increased 24.8%, or $1.9M, over 1QFY19.

  • Business Wire

    Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call

    Simulations Plus announced today that it will report 1st quarter fiscal year 2020 financial results on Jan. 9, 2020, with a webcast at 4:15 p.m. EST.

  • Business Wire

    Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor

    Simulations Plus today announced a collaboration with Bayer AG to develop important new capabilities in its ADMET Predictor machine learning software.

  • Business Wire

    Simulations Plus Partners with Large Pharmaceutical Company to Add New Capabilities to PKPlus

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to enhance the PKPlus™ software. “Following a rigorous evaluation of multiple commercial offerings, our partner selected PKPlus as the pharmacokinetics/toxicokinetics (PK/TK) modeling program to support the internal data platform that connects their global teams,” said Joshua Fohey, director of Operations for Simulations Plus.

  • Business Wire

    Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to modify the mechanistic oral absorption (ACAT™) model in GastroPlus® to support gastrointestinal disease research. “What an exciting opportunity we have to participate in a collaboration which will enhance and advance understanding of local drug disposition in the gut tissue to assist with the development of new therapies for gastrointestinal diseases,” said Viera Lukacova, director of Simulation Sciences for Simulations Plus.

  • Business Wire

    Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results

    Full-Year Revenue Increased 14.5% to $34 Million

  • Business Wire

    Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call

    Conference Call to be on Wednesday, November 13, 2019, at 4:15 PM ET

  • Business Wire

    Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it is supporting the drug development program for a lifesaving countermeasure to acute radiation syndrome (ARS) in a partnership with a global pharmaceutical company. DILIsym Services Inc. (DSS), an SLP company, will spearhead development of RADAsym™. The new QSP (Quantitative Systems Pharmacology) platform will allow for prediction of the effects of radiation on mice, non-human primates, and humans, as well as the impact of interventions on radiation syndrome.

  • Business Wire

    Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop the Virtual Bioequivalence (BE) Trial Simulator™ in GastroPlus®. “We are beyond pleased to announce this collaboration, which will enhance the GastroPlus physiologically based biopharmaceutics (PBBM) / physiologically based pharmacokinetic (PBPK) platform to evaluate population and formulation variability on the BE of different products,” said Viera Lukacova, director of Simulation Sciences for Simulations Plus.

  • Business Wire

    Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Friday, November 1, 2019, to shareholders of record as of Friday, October 25, 2019. Walt Woltosz, chairman of the board of directors, said, “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.06 per share per quarter.

  • Business Wire

    Simulations Plus Announces Leadership Changes at Cognigen

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Jill Fiedler-Kelly has been named President of the Cognigen division in addition to other leadership changes to support the ongoing growth of the Company’s Cognigen division. Ms. Jill Fiedler-Kelly, a co-founder of Cognigen who served as Vice President of Pharmacometric Services since 1992, has been promoted to President of the Cognigen division of Simulations Plus.

  • Business Wire

    DILIsym Releases NAFLDsym® Version 2A

    Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing

  • Business Wire

    Simulations Plus Upgrades Flagship GastroPlus

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.7 of its flagship physiologically based pharmacokinetic (PBPK) modeling platform, GastroPlus®.

  • Business Wire

    Cognigen Launches KIWI Version 4.0

    Cognigen Corporation, a Simulations Plus company (SLP) and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that it has released Version 4.0 of its KIWI™ Pharmacometric Communication and Collaboration Platform. KIWI is a private cloud-based, validated platform to efficiently and consistently organize, process, visualize, evaluate, and communicate modeling and simulation results. Since the introduction of KIWI 1.0 in 2011, our mission has been to provide pharmacometricians with the most efficient analysis environment possible.

  • Business Wire

    PMDA Adds Licenses of GastroPlus®

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus® software suite. John DiBella, Lancaster division president for Simulations Plus, said: “The adoption of physiologically based pharmacokinetic (PBPK) modeling to support various applications during the drug development process has increased over the years, partly driven by encouragement from global regulatory agencies.

  • Business Wire

    U.S. FDA Renews DILIsym Software Licenses

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Administration has renewed its multi-seat license for the company’s flagship quantitative systems toxicology (QST) modeling software, DILIsym®. The renewal provides DILIsym access to FDA employees across all FDA divisions.

  • Business Wire

    Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019

    Simulations Plus, Inc. , a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B.

  • Business Wire

    Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors. With a distinguished career spanning more than 35 years, Dr. LaVange brings expertise in biostatistics and experience with academia, commercial organizations, including Quintiles, the largest pharmaceutical outsourcing services company in the U.S., and government regulators, including a senior position at the U.S. Food and Drug Administration (FDA).

  • Business Wire

    FDA Purchases Bundle of ADMET Predictor® Licenses

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite. The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making. John DiBella, Lancaster division president for Simulations Plus, said: “For many years, the FDA has utilized our software across various departments, including the Office of Clinical Pharmacology, Office of Generic Drugs, and Office of Pharmaceutical Quality.